Nearly half of Alzheimer’s cases are mild, supporting a focus on early intervention
The great prevalence of mild disease underscores the need for interventions that may slow decline or prevent progression in dementia, researchers contend.
Alzheimer’s Research
FDA advisers vote ‘no’ on drug that may slow Alzheimer’s progression
If approved by the FDA, aducanumab would be the first-ever drug marketed to slow progression of the brain-wasting disease, according to its developer. But an advisory committee was unconvinced of the drug’s efficacy, voting 8 to 1 against recommending approval.
Alzheimer’s drug gets FDA support ahead of Friday vote on approval
Documents released on Wednesday show that the agency’s staff members already are enthusiastic about the drug’s prospects. If approved, aducanumab could be the first drug on the market to slow Alzheimer’s progression.
Study to examine severe side effects tied to Alzheimer’s drug combo
Millions of Medicare records will be used to analyze how two drug classes commonly used to treat Alzheimer’s may lead to a ‘prescription cascade’ when taken together.
Highly accurate Alzheimer’s blood test a ‘breakthrough,’ observers say
The experimental blood test rivals the accuracy of standard diagnostic methods and may soon prove to be a cost-effective, accessible tool in the clinical setting, according to some in the scientific community.
Alzheimer’s discoveries show new promise for drug development, expert says
The discovery of new biomarkers — along with a focus on repurposed drugs — are optimistic signs for Alzheimer’s research, according to a five-year analysis.
Biogen seeks FDA approval for Alzheimer’s drug; aims to be first to slow disease
Treatment with aducanumab reduced declines in memory, language, and activities of daily living performance, the drugmaker says.
Study suggests that Alzheimer’s drugs could reverse diabetes damage
Failed Alzheimer’s drugs could be repurposed to target an enzyme that may lead to heart attack and stroke, say investigators.
Clinical Briefs for Monday, April 13
More than 2,200 COVID-19 deaths in nursing homes … Lack of data, testing puts residents at risk of coronavirus: provider survey … More evidence found that ultrasound can aid in delivering future Alzheimer’s treatments … FDA approves first generic albuterol inhaler to meet rising demand
Biogen not giving up on Alzheimer’s treatment with mixed past
After a bit of a bumpy ride in 2019, Biogen’s injectable treatment for early Alzheimer’s is set for a late-stage clinical trial.
